anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
### Usual Initial Dosage

Paroxetine hydrochloride extended-release tablets should be administered as a single daily dose, usually in the morning. Patients should be started on 12.5 mg/day. Dose changes should occur in 12.5 mg/day increments and at intervals of at least one week. Patients were dosed in a range of 12.5 to 75 mg/day in the clinical trials demonstrating the effectiveness of paroxetine hydrochloride extended-release tablets. The maximum dosage should not exceed 75 mg/day. 

Patients should be cautioned that paroxetine hydrochloride extended-release tablets should not be chewed or crushed and should be swallowed whole. 

### Maintenance Therapy

Long-term maintenance of efficacy with the immediate-release formulation of paroxetine was demonstrated in a 3 month relapse prevention trial. In this trial, patients with panic disorder assigned to immediate-release paroxetine demonstrated a lower relapse rate compared to patients on placebo. Panic disorder is a chronic condition and it is reasonable to consider continuation for a responding patient. Dosage adjustments should be made to maintain the patient on the lowest effective dosage and patients should be periodically reassessed to determine the need for continued treatment.
The present invention relates to a method for preparing highly water soluble chilli oil powder. The present invention is characterized in that the present invention has the steps as follows: (1) a hydroxypropyl-beta-cyclodextrin aqueous solution with the mass concentration of 5 to 40% is prepared; (2) horse radish oil with an equal molar ratio is added to the hydroxypropyl-beta-cyclodextrin aqueous solution and is counted by allyl isosulfocyanate; (3) the aqueous solution is stirred by 4 to 6 hours under normal temperature; (4) the aqueous solution is carried out with freeze drying or spray drying to obtain microcapsule powder. The present invention uses isosulfocyanate which is an effective component in the hydroxypropyl-beta-cyclodextrin and the horse radish oil to cover for obtaining solid molecule microcapsule powder with excellent water solubility. By a suspension liquid method, the horse radish oil microcapsule covered by the hydroxypropyl-beta-cyclodextrin can be prepared. By testing, the isosulfocyanate content of the horse radish oil microcapsule can reach 30 to 45 mg/g. isosulfocyanate in a molecule microcapsule has excellent heat stability. In an aqueous solution, since the protective action of the shell of the cyclodextrin, a reaction rate between the isosulfocyanate and nucleophilic reagents such as water, hydroxyl, etc. is greatly reduced.
PURPOSE: A novel melanin biosynthesis inhibitor is provided, which inhibits production of melanin by impediment of tyrosinase activity without side effect, so can be used in cosmetics for prevention of skin aging, protection of skin, and whitening effect, medicines for liver spots, freckles, spots or hyperpigmentation during pregnancy period, and food additives for inhibition of browning. CONSTITUTION: The novel melanin biosynthesis inhibitor contains extract from needles(main ingredients are acetophene, p-vinylphenol, leucoanthocyan, shikimic acid, protocatechuic acid) and barks(main ingredients are shikimic acid, protocatechuic acid) of Pinus densiflora Sieb. et Zucc. and Pinus koraiensis Sieb. et Zucc., or mugwort extract. A process for the preparation of extract from needles and barks of Pinus densiflora Sieb. et Zucc. and Pinus koraiensis Sieb. et Zucc., or mugwort extract comprises: eliminating sugar and protein ingredient using enzyme, and removing fat; extracting with ethanol, methanol, acetone, ethylacetate while heating to get free-type phenolic acid fraction, soluble ester-type phenolic acid, non-soluble phenolic acid and leucoanthocyan.
Orthognathic surgery has a high incidence of postoperative nausea (PON) and vomiting (POV), delaying mobility initiation and postoperative recovery. Bleeding is another risk associated with this surgical procedure. We aimed to compare total intravenous anesthesia (TIVA) and volatile anesthesia in patients undergoing orthognathic surgery in terms of postoperative nausea and vomiting (PONV) incidence and hemodynamic changes. This retrospective study included 82 patients who underwent bilateral sagittal split ramus osteotomies at Saga University Hospital between April 2016 and April 2021. We compared the effects of TIVA and volatile anesthesia on PONV onset after surgery, acute postoperative hemodynamic changes (blood pressure and heart rate), and factors contributing to PONV. PON was significantly lower in the TIVA group than in the volatile anesthesia group. The total dose of fentanyl contributed to the onset of POV, while the onset of PON was associated with low volumes of fluid infusion and urine in the TIVA and volatile anesthesia groups, respectively. Furthermore, post-extubation hemodynamic change was significantly smaller in the TIVA group than in the volatile anesthesia group. Therefore, TIVA could have a reduced risk of PONV and hemodynamic changes in patients undergoing orthognathic surgery. Employing TIVA could mitigate perioperative complications and enhance patient safety.
A method of using a transfer factor formulation to improve the success rate of a human COS or COS/IUI procedure. The transfer factor formulation consists of at least transfer factor, and may also include lactic acid generating bacteria, and/or glucans. The transfer factor formulation, administered correctly, improves the probability of achieving conception via COS/IUI. Both men and women can receive transfer factor formulation. Dosage amounts are adjusted for body weight. Consumption frequency may be adjusted in response to hormonal measurements. Typically, consumption of the formulation begins three to 100 days before a planned COS/IUI procedure.
Participants will be treated for a total of 12 weeks. Participants will receive MK-8189-matching placebo QD in the acute treatment period from Week 1-6 followed by MK-8189 24 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
This study uses 2x2 design to test external beam radiotherapy (46 Gy in 23 daily fractions) with and without HDR brachytherapy (2 fractions of 9 Gy versus 4 fractions of 7 Gy) with and without weekly Cisplatin (40 mg/sqm) The overall objective was to test the clinical outcome and toxicity of a resource-sparing schedule of radiotherapy with or without chemotherapy treatment for cervix cancer, to detect molecular markers that will predict tumor control/resistance and to establish whether E6 and E7 viral proteins predict cellular radiosensitivity in oxic and hypoxic conditions in vitro and tumor control/resistance in vivo. A new component of the CRP was added, for which the objective is to optimize the data capture, provide more details of normal tissue outcomes following cancer treatments in developing countries and validate this approach using patients participating in the ongoing CRP. This will be achieved by exploring data capture using the questionnaire template on a computer in face-to-face interviews ("active" data collection) and comparing it with standard data collection obtained from the clinical notes ("passive" data collection) during the still ongoing CRP E3.30.24. The method of data collection will be chosen at random for each case stratified by centre. The reason for using an ongoing CRP is that it will test the usefulness of the new method and validate it in a multicentre study. During the performance of the new CRP, the same institutions as for E3.30.24 will be engaged.
Hepatitis C virus (HCV) is highly dependent on host cellular factors for viral propagation. Using high-throughput next-generation sequencing, the present inventors analyzed the host transcriptomic changes and identified 30 candidate genes which were upregulated in cell culture-grown HCV (HCVcc)-infected cells. Of these candidates, the present inventors selected Rab32 for further investigation. Rab32 is a small GTPase that regulates a variety of intracellular membrane-trafficking events in various cell types. In the present invention, the present inventors demonstrated that both mRNA and protein levels of Rab32 were increased in HCV-infected cells, and further showed that HCV infection converted the predominantly expressed GTP-bound Rab32 to GDP-bound Rab32, contributing to the aggregation of Rab32 and subsequently making it less sensitive to cellular degradation machinery. In addition, GDP-bound Rab32 selectively interacted with HCV core and deposited the core into Rab32-derived aggregated structures in the perinuclear region, which were likely to be viral assembly sites. By using RNA interference technology, the present inventors demonstrated that Rab32 was required for the assembly stage but not for other stages of the HCV life cycle. Taken together, these data suggest that HCV may modulate Rab32 activity to facilitate virus assembly.
The present invention relates to externally applied medicine for curing respiratory tract diseases, which is ointment prepared by raw materials of the following weight proportioning and a method. Externally applied medicine is prepared from 1 to 3.5 wt. % of ephedra, 4 to 9 wt. % of apricot kernel, 6 to 12 wt. % of baical skullcap root, 9 to 15 wt. % of honeysuckle flower, 9 to 15 wt. % of pepperweed seed, 9 to 15 wt. % of perilla fruit, 3 to 9 wt. % of earthworm, 3 to 9 wt. % of stiff silkorm, 3 to 9 wt. % of araceae, 6 to 12 wt. % of blackberry lily. By cleaning, decoction, filtration and concentration, the raw materials are formed into extractum. Auxiliary materials composed of 1 to 3 wt. % of raw material powder are added to the raw materials to prepare extract. After the extract is processed by asepsis, the extract is packed. The medicine is capable of realizing externally curing diseases in a body, is convenient for use, has the effect for relieving cough and reducing sputum, clearing away heat and toxic material, expanding bronchi, improving lung microcirculation, reducing PaCO2 and enhancing PaO2, is easy to administer and has good curing effect. By the method provided by the present invention, the acute bronchitis and the pneumonia of babies can be properly cured.
Patients in this arm will receive low fiber diet starting postoperative day 1. This is currently the standard protocol at our institution.
The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
PURPOSE: A novel Lactobacillus sakei K101(KCCM 11175P) which prevents and treats inflammatory diseases or immune diseases is provided to induce the expression of cytokines such as TNF-alpha. CONSTITUTION: A Lactobacillus sakei K101(KCCM 11175P) prevents and treats inflammatory diseases or immune diseases. A food composition contains the strain or crushed materials, a culture or an extract thereof, or lipoteichoic acid isolated from the strain. A pharmaceutical composition for preventing and treating inflammatory diseases or immune diseases contains the strain or crushed materials, a culture or an extract thereof, or lipoteichoic acid isolated from the strain. A feed composition contains the strain or crushed materials, a culture or an extract thereof, or lipoteichoic acid isolated from the strain. The pharmaceutical composition is manufactured in the form of powder, granules, tablets, capsules, a suspension, an emulsion, syrup, an oral formulation of aerosol, an external use formulation, a suppository, or a sterilized injection liquid.
Patients start with a home-based exercise program, supported by an internet-based tool (Step 1). Patients are then assessed for degree of improvement in symptoms, and then can step up sequentially to telephone or video-based physical activity coaching (Step 2) and physical therapy (Step 3) if they do not make clinically relevant improvements in prior steps.
Hirsutism of the lanugo type, mainly on the forehead, back and limbs, occurs most commonly in children and women and may be cosmetically unacceptable. It subsides on discontinuation of the drug.

Hyperglycemia or glycosuria may require reduction in dosage in order to avoid progression to ketoacidosis or hyperosmolar coma.

Gastrointestinal intolerance may include anorexia, nausea, vomiting, abdominal pain, ileus, diarrhea, transient loss of taste.

Tachycardia, palpitations, increased levels of serum uric acid are common.

Thrombocytopenia with or without purpura may require discontinuation of the drug. Neutropenia is transient, is not associated with increased susceptibility to infection, and ordinarily does not require discontinuation of the drug. Skin rash, headache, weakness, and malaise may also occur.
Participants assigned to the active comparison condition will receive therapy as usual - i.e., general, open-ended, non-manualized supportive counseling provided by an NDT therapist. In the absence of any evidence-based therapies available for Deaf clients, this unstructured therapy approach is the current standard of care in the field of Deaf mental health. All NDT therapists are Deaf, fluent in ASL, and specialize in issues common to Deaf individuals seeking mental health care. Like the experimental condition, participants will receive 12 one-hour, weekly individual therapy sessions via NDT's secure virtual therapy platform. Length of treatment is limited to six months; number of completed sessions will be tracked as a measure of participant adherence.
INTRODUCTION: With the increasing life expectancy of Western populations, more octogenarians are presenting with large abdominal aortic aneurysm (AAA). Endovascular repair offers a less invasive alternative and older patients who may not have been offered open repair in the past are now being considered for elective repair with this approach. Age in isolation may not be the only consideration in recommending elective aneurysm repair. We aimed to review the literature on complex endovascular AAA repairs (mainly fenestrated endovascular aortic repair [FEVAR]) in octogenarians.
METHODS: A literature search was conducted using the Ovid Medline®, Embase® and Cochrane Library databases for articles published up to January 2022. All English language publications from 1995 onwards were eligible for inclusion. Search terms included: "FEVAR", "F-EVAR", "fenestrated EVAR", "fenestrated endovascular aortic repair", "fenestrated endovascular aneurysm repair", "fenestrated AAA repair", "fenestrated endograft", "fenestrated stent graft", "fenestrated", "endograft", "EVAR", "octogenarian", "elderly", "above 80" and "over 80".
METHODS: The literature search identified 134 potential articles. Following qualitative assessment by two independent appraisers, this was refined to 11 studies, in accordance with the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement.
RESULTS: The primary outcome measure was 30-day mortality, which was highly variable, ranging from 0% to 9% in octogenarians and from 0% to 5% in non-octogenarians. However, these differences were only found to be statistically significant in two studies. The secondary outcome measures included technical success rates, major adverse events, reintervention rates, freedom from reintervention, target vessel patency, freedom from target branch instability, and length of hospital and intensive care unit stay. No statistically significant differences were found between octogenarians and non-octogenarians. Long-term survival was significantly lower for octogenarians in two studies.
CONCLUSIONS: The perioperative outcomes of FEVAR in octogenarians are comparable with those of younger patients. FEVAR therefore appears to be an acceptable option for complex endovascular aneurysm repairs in carefully selected octogenarians. Nevertheless, this review highlights the paucity of published data on the outcomes of endovascular repair of complex aneurysms in octogenarians.
Patients with leukodystrophies (LDs) of unknown etiology are a heterogeneous group but constitute the second largest group of genetic white matter diseases. The purpose of this study is to: (a) define novel homogeneous groups of patients with LDs and (b) work toward finding the cause of these disorders. In order to achieve these goals, patients with LDs of unknown cause will be analyzed clinically, neurophysiologically, biochemically and genetically. Patients would have been diagnosed as having no known leukodystrophies at outside centers. At the Clinical Center, such patients will undergo a series of neuropsychological, blood, urine, spinal fluid, radiological, and peripheral tissue pathological tests. Some of these tests will be part of a standard battery while others will be tailored to individual patients. Patients will be followed for 3 years. Patients will be screened for mutations in genes coding for structural myelin proteins. In some patients in whom all tests yielded no information regarding the etiology of their disease, open brain biopsy will be considered. Brain biopsy tissue will be evaluated using a novel combination of approaches including detailed pathological, immunohistochemical, and biochemical analysis of myelin proteins and lipids. Oligodendroglial biology and expression of myelin genes in the brain will also be investigated in situ. It is hoped that the present study will help clarify the nosology of the leukodystrophies and significantly advance our understanding of the pathogenesis of these diseases.
With the Korle-Bu modified partograph, uterine contractions will be assessed every hour (60 minutes), fetal heart will be assessed every 30 minutes and maternal pulse every hour. All other assessments remain as for the traditional partograph.
OBJECTIVES: Long COVID has received much attention as a complex multi-system disease due to its serious impact on quality of life. However, there remains inconsistent results in terms of risk factors, and a prediction model for the accurate prediction of long COVID is still lacking.
STUDY DESIGN: Cross-sectional study.
METHODS: In this retrospective study, a community population from the Futian District of Shenzhen, Guangdong Province, China, were included. Data were collected from September to December 2023 using an electronic questionnaire. Logistic regression analyses were used to identify predictors of long COVID. Pre-infection and post-infection prediction models (with/without post-infection characteristics) were developed, and the C-index was used to evaluate accuracy.
RESULTS: In total, 420 patients infected COVID-19 were included. The prevalence of long COVID was 32.9 %. The most common symptoms of long COVID were weakness/fatigue, persistent cough and cognitive dysfunction. Independent predictors of long COVID included in the pre-infection model were age, long-term medication, and psychological problems such as stress and doing things without enthusiasm/interest before COVID-19 infection (C-index: 0.721). Independent predictors included in the post-infection model were age, inability to concentrate before COVID-19 infection, and symptoms of weakness/fatigue, abnormal smell/taste, diarrhoea, eye conjunctivitis and headache/dizziness during the acute-phase (C-index: 0.857).
CONCLUSIONS: Age, psychological problems before COVID-19 infection and acute-phase symptoms were important risk factors of long COVID. Results from the pre-infection model provide guidance for non-infected individuals on how to prevent long COVID. Results from the post-infection model can be used to accurately predict individuals who are at high risk of long COVID and help design treatment plans for patients in the acute phase.
1459262 Skin test cover V P PIRILA 5 March 1974 [15 March 1973] 9934/74 Headings A5B and A5R A skin test cover containing a test substance, the cover being of an inflexible and liquid and gas impermeable material and being suitable for use in epicutaneous tests, comprises a plate portion 1 and a collar portion 2 extending from the circumference of the plate portion and devoid of any flange about the collar portion. The plate portion may be planar and circular, Fig. 1 (not shown), and is may be formed integrally with the collar portion The cover may 'be made of metal, such as aluminium, or of plastics material. The collar portion may be cylindrical, Fig. 5 (not shown) or have the general shape of a truncated cone. The edge 4 of the. collar portion may be rounded, and it may be provided with a generally U-shaped groove (3), Fig. 2 (hot shown). The total diameter of the cover may be 10 mm, or other than this depending on the material, and on the required size of test area. The cover may be contained in a sterile pack. In use, the test substance 5 either incorporated in e.g. petroleum jelly or as a solution absorbed in filter paper is in contact with the skin surface 6 of a patient, the cover being fastened to the skin by tape 7.
The purpose of this study is to determine the safety and tolerability, as well as the biochemical effects of choline bitartrate over a 6-month treatment period in a moderately sized population harboring at least one copy of the APOE4 gene. APOE is a protein involved in lipid transport. Studies show that the APOE4 variant is strongly associated with an increased risk of Alzheimer's Disease. It is unclear how APOE4 results in an increased risk for AD, but a recent study identified a novel molecular pathway, which showed that APOE4-induced dysfunction of lipid metabolism in neurons by cellular accumulation of unsaturated lipids. The investigators hypothesize that choline supplementation normalizes the APOE4-mediated dysregulation by normalizing the Kennedy pathway in neuronal cells, thus stabilizing the lipid metabolism and concomitantly restoring normal cell function by increasing phosphatidylcholine activity via the Kennedy pathway. To evaluate this, the investigators will test if choline supplementation will decrease the ratio of unsaturated lipids to saturated lipids (the fatty acid desaturation index) in cerebrospinal fluid by 15% and increase phosphatidylcholine by 100%.
The intervention consists of a 20% chance of receiving a small cash incentive of $4.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
This group will consist of participants age 60+ who will be assessed for malnutrition and sarcopenia. Participants in this group will undergo chemotherapy and/or receive cancer drugs (as part of standard care). Participants in this group will receive different assessments when they start induction therapy to measure their nutritional health and the severity of their sarcopenia.